The MMRF provides CME-accredited educational programs for healthcare professionals to learn more about multiple myeloma as well as current and emerging treatment options, including clinical trials from key leaders in myeloma. Access up-to-date information.
Treating Multiple Myeloma in 2017: New Agents, New Challenges
a webinar on the current state of practice for patients with multiple myeloma, will be held on Tuesday, December 13, 2016 from 4:00 to 5:00 PM (ET).
Conducted by Dr. Thomas G. Martin, III, from the University of California, San Francisco Medical Center and Dr. Suzanne Lentzsch from Columbia University Medical Center, this webinar will review the clinical data underlying the FDA’s approval of the latest myeloma drugs and discuss where and how these newly approved agents fit in the current myeloma treatment schema.
Multiple Myeloma Patient Management: New Agents, New Challenges
Preceding the 58th American Society of Hematology (ASH) Annual Meeting & Exposition
The multiple myeloma (MM) therapeutic landscape has significantly expanded, with 10 new drug approvals in the last 12 years. To help hematologist-oncologists keep pace with the rapid advancements in treatments, this satellite symposium will provide updated information on the optimal strategies for managing patients with MM.
The symposium will incorporate specially developed iPad-based learning elements to enhance interactivity, deepen engagement, and provide learners with opportunities to answer case-based questions that will be discussed by a panel of experts.
At the conclusion of this activity, participants should be able to:
Evaluate current clinical evidence on tools to define patient prognosis and risk stratification
Factor the indicated uses, mechanisms of action, and safety of newly available therapies when determining treatment plans for patients with MM
Select treatment combinations in the frontline and salvage settings to achieve the most durable response while balancing the risk for toxicities
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this symposium for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Expert Perspectives in Advancing Treatment Paradigms for Multiple Myeloma
Significant progress in the treatment of multiple myeloma has been made over the last decade resulting in improved clinical outcomes for patients and transforming this disease to a chronic condition that can be managed over a longer course of years. The rapid pace of scientific developments has led to a number of novel and promising therapies that have been approved or submitted for approval within the last year. As more clinical trials are progressing, treatments for myeloma will continue to advance. Novel therapeutic strategies have the potential to change current treatment and management algorithms for multiple myeloma. As treatments continue to evolve, it is imperative that nurses understand new modalities and translate new information promptly.
Since nurses often act as advocates on behalf of the patient and are integral in the management of treatment of side effects and physiological manifestations of multiple myeloma, it is becoming increasingly important that they be knowledgeable in both the basics of standards of care and any new data/therapies that could help to improve patient outcomes.
This live, interactive CNE accredited activity will provide nurses who care for patients with multiple myeloma with information regarding the pathology of multiple myeloma as well as the state-of-the art changes in treatment paradigms that provide practical and reliable information that promote the efficient application of current standards of care into clinical practice and ultimately improve patient outcomes.
September 7th: LE MERIDIEN CHICAGO OAKBROOK CENTER- OAK BROOK, IL
September 13th- ITALIANISSIMO RISTORANTE- STATEN ISLAND, NY
September 13th – RUTH’S CHRIS- BIRMINGHAM, AL
September 14th – LOS ANGELES, CA
September 22nd – LIBERATORE’S RESTAURANT- BALTIMORE, MD
November 5th – LAS VEGAS, NV
The Evolving State of Relapsed/Refractory Multiple Myeloma Treatment
A CNE satellite symposium to be held during the Oncology Nursing Society’s 41st Annual Congress
In 2015 four new agents were approved for the treatment of multiple myeloma (MM) in the
salvage setting, equipping oncology health professionals with more therapeutic options than ever before. But for oncology nurses, this progress also brings the challenge of managing new treatment-related toxicities. This interactive symposium will feature the use of iPads to provide current information to help oncology nurses maximize treatment outcomes for patients with relapsed/refractory MM.
April 28, 2016
Lone Star Ballroom DEF
Grand Hyatt San Antonio
600 E. Market Street
San Antonio, TX
Learn more and register: https://www.regonline.com/mmrfnursesymposium2016
Chicago Multiple Myeloma Rounds – Mark Your Calendars!
Innovative and Developing Therapeutic Approaches in the Management of Multiple Myeloma – Application to Current Practice 2016
Key Note Speaker:
Robert A. Kyle, MD
Mayo Clinic Rochester
February 10, 2016
Chicago Marriott at Medical District/UIC
Learn more and register: www.plexuscomm.com/mmrounds
Building on Myeloma Therapy: Emerging Molecular Targets
and Immunotherapeutic Approaches
Presentations available from the CME-Certified Satellite Symposium
Sponsored by the MMRF
56-Year-Old Woman Relapsing Following Induction Therapy and Autologous Stem Cell TransplantationIn this interactive e-learning activity for oncology nurses, participants review the latest updates in MM patient care and make clinical decisions to maximize treatment outcomes for a virtual patient with relapsed/refractory MM. Earn your credits now
Multiple Myeloma Virtual PracticeA CME-certified curriculum on myeloma patient care. Earn your credits now
- New Developments in Multiple Myeloma TreatmentTwo interactive modules reviewing new therapies and highlighting strategies for optimizing treatment outcomes:
– The Main Conference Room presentation reviews recent data on myeloma diagnosis and management and follows a patient case through the course of his disease.
– In the RME Hot Seat, myeloma experts discuss the use of elotuzumab vs daratumumab in patients with relapsed/refractory disease; determining which agent to use at disease progression in lenalidomide-sensitive patients; the potential use of PD-1 inhibitors in combination therapy; and several other subjects of relevance to clinicians who see myeloma patients. Earn your credits now
The Swiftly Changing Landscape: Multiple Myeloma Trials and TreatmentsEarn your credits now
Multiple Myeloma Updates from the 2015 ASH Annual MeetingEarn your credits now
Multiple Myeloma Virtual InstituteA CME-certified curriculum on myeloma patient care. Earn your credits now
- A series of evidence-based presentations on factors that are critical to the successful management of patients with multiple myeloma. View featured presentations:
- How Is Risk Assessment Useful?
- From Smoldering to Symptomatic Myeloma
- Should We Strive for Deepest Remission Possible in All Patients?
- Balancing Maximum Benefit With Quality of Life
- Clinical Considerations for Treatment Selection in Relapsed/Refractory Disease
- Multiple Myeloma Treatment: A Look Forward
- Personalizing Multiple Myeloma Treatment for Maximum BenefitA series of evidence-based presentations on factors that are critical to the successful management of patients with multiple myeloma: Earn your credits now
- Adult Woman With Elevated Protein (Virtual Case Study)Interactive, video-based patient case that challenges learners to assess a myeloma case, interpret lab results, formulate a treatment plan, and determine a prognosis. Earn your credits now
- 60-Year-Old Woman Following Induction Therapy for Active MM (Virtual Case Study)Interactive, video-based patient case of relapsed myeloma that challenges learners to determine appropriate therapies and monitor disease activity. Earn your credits now